Bayer plans to acquire Perfuse Therapeutics in a deal worth up to $2.45 billion, aiming to strengthen its eye care pipeline. The purchase includes PER-001, currently in clinical trials and targeting glaucoma and diabetic retinopathy, two major causes of vision loss. The move signals Bayer’s push to expand treatment options through late-stage development.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
